PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks
and other complications of their blood vessels. New therapies are needed to prevent this
complication. The purpose of this study is to establish the role of the medication
pioglitazone in improving the function of the blood vessels and heart and decreasing the risk
of future atherosclerosis development in individuals with rheumatoid arthritis. As a
secondary aim-point, we will evaluate the efficacy of pioglitazone in improving rheumatoid
arthritis disease activity and markers of inflammation.
Phase:
Phase 3
Details
Lead Sponsor:
University of Michigan
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)